Storm Therapeutics
Targeting pathways that modify RNA to deliver novel cancer therapeutics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $30.0m | Series B | |
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | 664 % | 25 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | (1801 %) | (254 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (1944 %) | (219 %) | (151 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | - | 1521 % | 283 % | - |
Source: Company filings or news article
Related Content
STORM Therapeutics is an emerging biotechnology company based in Cambridge, UK, specializing in the field of RNA epigenetics. The company focuses on developing small molecule inhibitors that target RNA modifying enzymes, which are crucial for the treatment of cancer. RNA epigenetics involves the study of chemical modifications on RNA molecules, which can influence gene expression and cellular function. By targeting these modifications, STORM Therapeutics aims to develop innovative therapies that can potentially transform cancer treatment.
The company primarily serves the healthcare and pharmaceutical sectors, targeting oncologists, researchers, and medical institutions. Operating in the highly specialized market of RNA-based therapies, STORM Therapeutics leverages cutting-edge research and development to create its products. The business model revolves around the discovery and development of proprietary drug candidates, which are then licensed or partnered with larger pharmaceutical companies for further development and commercialization. This approach allows STORM Therapeutics to generate revenue through licensing fees, milestone payments, and royalties on sales of successfully commercialized drugs.
Keywords: RNA epigenetics, small molecule inhibitors, cancer treatment, biotechnology, Cambridge UK, RNA modifying enzymes, oncology, drug development, healthcare, pharmaceutical.